NAC Supplement Cuts Newborn Complications in Preterm Births, Study Finds

A new clinical trial has found that giving pregnant women N-acetylcysteine (NAC) when facing imminent preterm birth reduces acute complications in newborns. The study, which was randomised and placebo-controlled, suggests this antioxidant could become a useful tool in managing high-risk pregnancies. Researchers now call for further investigation into its broader applications.

The trial showed that NAC supplementation, when administered at critical times before preterm delivery, lowered the risk of neonatal complications. Unlike some treatments, it did not shorten gestation or harm fetal growth. This finding is particularly significant as preterm birth remains a leading cause of newborn illness.

NAC works by boosting glutathione levels, helping cells neutralise harmful free radicals. It also reduces inflammation by affecting NF-κB pathways, which lowers the production of pro-inflammatory cytokines. As a result, mothers in the study experienced fewer infections and inflammatory issues. The results open possibilities for combining NAC with existing treatments, such as corticosteroids and tocolytics. Researchers suggest this multi-pronged approach could improve outcomes for both mother and baby. They also highlight the value of pairing biochemical tests with clinical observations to assess pregnancy interventions more effectively. While promising, the study’s authors stress the need for larger, multi-centre trials. These would confirm whether the benefits hold across different populations and medical settings.

The trial presents NAC as a potential addition to preterm birth management, offering a way to reduce complications without harming fetal development. Further research may also explore its role in other pregnancy-related conditions, such as preeclampsia or fetal growth restriction. For now, the findings provide a foundation for developing more comprehensive strategies in perinatal care.